

Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma

Maria Romina Girotti, Filipa Lopes, Natasha Preece, Dan Niculescu-Duvaz, Alfonso Zambon, Lawrence Davies, Steven Whittaker, Grazia Saturno, Amaya Viros, Malin Pedersen, Bart M.J.M. Suijkerbuijk, Delphine Menard, Robert McLeary, Louise Johnson, Laura Fish, Sarah Ejima, Berta Sanchez-Laorden, Juliane Hohloch, Neil Carragher, Kenneth Macleod, Garry Ashton, Anna A. Marusiak, Alberto Fusi, John Brognard, Margaret Frame, Paul Lorigan, Richard Marais,* and Caroline Springer*

*Correspondence: richard.marais@cruk.manchester.ac.uk (R.M.), caroline.springer@icr.ac.uk (C.S.)
<http://dx.doi.org/10.1016/j.ccell.2017.02.007>

(Cancer Cell 27, 85–96, January 12, 2015)

The authors have noted an error in Figure 6A of the originally published version of this article. The image for pERK (top right panel) was incorrectly duplicated from Figure 4E (top right panel). The corrected Figure 6 is shown here. This error does not alter the original conclusions of the study, but the authors wish to apologize for this oversight and any confusion that may have resulted.




Figure 6. CCT196969 and CCT241161 Inhibit Tumors with Acquired Resistance to Dabrafenib plus Trametinib